Skip to main content
Spexis AG logo

Spexis AG — Investor Relations & Filings

Ticker · SPEX ISIN · CH0106213793 LEI · 391200S8HJE1I96FIG04 SW Manufacturing
Open in API
Filings indexed 194 across all filing types
Latest filing 2022-03-09 Report Publication Anno…
Country CH Switzerland
Listing SW SPEX

About Spexis AG

https://www.polyphor.com/

Spexis AG is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for rare diseases and oncology. The company leverages its expertise in macrocycle technology to create novel drug candidates designed to address high unmet medical needs. Its pipeline is advanced through a strategy that includes in-house discovery, development, in-licensing, and the acquisition of promising molecules. The primary therapeutic areas of interest include rare diseases and cancer, with an additional focus on antimicrobial resistance.

Recent filings

Filing Released Lang Actions
Strategy Update and 2021 Financial Results
Report Publication Announcement Classification · 99% confidence The document is an 'Ad hoc announcement pursuant to Art. 53 LR' from Spexis AG, dated March 9, 2022. The core content announces that the company 'will publish its full-year financial results for 2021 on March 24' and will host an earnings call. This document is not the full financial report (10-K or IR) itself, nor is it the transcript of the call (CT). It is an announcement about the future publication of results and the associated call details. This fits the definition of a Report Publication Announcement (RPA), which signals the upcoming release of a major report, or potentially a general Regulatory Filing (RNS) if RPA is too specific. Given the explicit mention of announcing the publication date of financial results and the associated call, RPA is the most precise fit, as it announces the report's release.
2022-03-09 English
Spexis to present strategy update and full-year 2021 financial results on March 24, 2022
Report Publication Announcement Classification · 99% confidence The document is a short announcement (4512 characters) dated March 9, 2022, stating that Spexis AG 'will publish its full-year financial results for 2021 on March 24' and will host an earnings call. This is not the actual financial report (10-K or IR) but an announcement about the future release of results and the associated conference call details. According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement detailing the publication of a report falls under Report Publication Announcement (RPA). It also provides details for an earnings call, which might suggest CT, but the primary purpose of this specific document is to announce *when* the results and call will happen, making RPA the most accurate classification for this pre-release notice.
2022-03-09 English
CARB-X milestone
Capital/Financing Update Classification · 99% confidence The document is identified by the RNS Number header and contains an 'Ad hoc announcement pursuant to Art. 53 LR'. It details a specific business event: achieving a milestone in a research program (thanatin derivatives) and receiving associated funding from CARB-X. This type of announcement, which is a material, non-public event disclosure made via a regulatory news service (RNS), fits best under the general 'Regulatory Filings' category, as it is not a full financial report (10-K, IR), a management discussion (MDA), an earnings release (ER), or a specific corporate action like a dividend (DIV) or share transaction (POS). The footer explicitly mentions that the information is provided by 'Reach, the non-regulatory press release distribution service of RNS,' confirming its nature as a general regulatory/press announcement that doesn't fit a more specific financial filing code.
2022-03-03 English
Spexis achieves first CARB-X milestone for its thanatin derivatives program and receives funding of up to USD 1.9 million to initiate lead optimization
Capital/Financing Update Classification · 99% confidence The document is explicitly labeled as an "Ad-hoc announcement pursuant to Art. 53 LR" and details a specific event: achieving a milestone in a research program (thanatin derivatives) and receiving associated funding from CARB-X. This type of announcement, which reports on a significant, non-periodic corporate event (like a grant award or research progress), is typically classified as a general regulatory announcement or news release that doesn't fit the strict definitions of 10-K, ER, or IR. Since it is a specific, material corporate update released outside of scheduled financial reporting, and it doesn't fit the definitions for financing (CAP, which is usually debt/equity issuance), management changes (MANG), or dividend notices (DIV), the most appropriate general category for material, non-standard regulatory news is 'Regulatory Filings' (RNS), which serves as the fallback for miscellaneous regulatory announcements.
2022-03-03 English
Polyphor closes merger with EnBiotix and is renamed Spexis
Delisting Announcement Classification · 99% confidence The document is titled 'News Details' and begins with 'Ad-hoc | 30 December 2021 07:15'. It explicitly states it is an 'Ad hoc announcement pursuant to Art. 53 LR' and details the closing of a merger between Polyphor and EnBiotix, including a name change to Spexis, changes in the Board of Directors, and an overview of the combined company's pipeline. This content describes a significant corporate event (merger/change of control/management change) announced via an immediate, unscheduled regulatory filing mechanism common in European exchanges (indicated by 'Art. 53 LR' and SIX Swiss Exchange listing). While it contains management changes (MANG) and capital structure elements (CAP), the primary nature is a major corporate action announcement. Since there is no specific code for a 'Merger Announcement' or 'Ad-hoc Filing' that covers all major corporate actions, and given the significant management and structural changes announced, it is best classified as a general Regulatory Filing (RNS) or potentially MANG if the focus was solely on the board change. However, the core event is the merger closing. Since 'TAR' (M&A Activity) is defined for merger *proposals* or *takeover bids*, and this is the *closing* of a merger, it fits best under the general 'Regulatory Filings' (RNS) as a catch-all for significant, non-standard reports, or potentially 'CAP' if the financing aspect was dominant, but the merger is the headline. Given the context of immediate, unscheduled regulatory disclosure ('Ad-hoc'), RNS is the most appropriate fallback for significant, non-periodic corporate events not covered by specific financial reports (10-K, IR, ER).
2021-12-30 English
Polyphor to inform about the financing of its merger partner EnBiotix
M&A Activity Classification · 95% confidence The document is an 'Ad hoc announcement' dated December 29, 2021, detailing that Polyphor's merger partner, EnBiotix, has completed a convertible debenture raise of USD 11 million. This financing is described as the 'last major step towards the closing of the merger'. The core subject is a financing event related to a corporate transaction (merger). This fits best under the 'Capital/Financing Update' category (CAP), as it explicitly discusses the completion of a financing round (convertible debenture raise) that enables a subsequent corporate action (merger closing). While it relates to a merger (TAR), the primary focus of this specific announcement is the successful completion of the financing component.
2021-12-29 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.